Share

Moleskine and Pierrel run against the tide on the Stock Exchange

The company in the historic diary benefits from an upgrade that arrived after the publication of positive quarterly accounts – For Pierrel, on the other hand, the signing of an agreement for the distribution of a drug in the United States is decisive.

Moleskine and Pierrel run against the tide on the Stock Exchange

Counter-current increases for shares on the Stock Exchange Pierrel e Moleskine, which at the end of the morning gained respectively 7,8 and 4,6% (to 0,8295 and 1,508 euro), recording the two best increases of all of Piazza Affari on the MTA. In the same minutes, the Ftse Eb travels down by 1,1%, in line with the trend of the other main European lists, all weighed down by the words of the governor of the Fed, Janet Yellen, according to which "prices on the Stock Exchanges are too high".   

Purchases on Moleskine they took off after the upgrade of Exane Bnp Paribas, which raised the target price on the stock by 6%, to 1,80 euro. Yesterday the company of the historic agenda had communicated the results of the first quarter, which closed with positive numbers. 

Turnover, net of revenues from the sale of displays and other extraordinary income, grew by 33,5% on the year, to 23,125 million (+19,7% at constant exchange rates). Ebitda, net of the effect of non-recurring charges, grew by 49,7% to 5,26 million (+18,9% at constant rates). Finally, the adjusted net profit increased by 123,3% to 3,059 million (+43,8%).

“The growth trajectory we are recording to date makes us confident that we can reach our targets for the year,” Moleskine CEO Arrigo Berni wrote in a note. In 2015, the company aims to achieve net revenues between 115 and 120 million and an Ebitda between 37 and 38 million at constant exchange rates.

As for Pierrel, today's rally comes after the three-year agreement signed by the subsidiary Pierrel Pharma with the North American company NDC Inc. for the distribution of the dental anesthetic Orabloc (Articaine Pierrel) in the United States. 

“This agreement – ​​underlined Fabio Velotti, sole director of Pierrel Pharma – marks a very significant moment in Pierrel's strategy in the USA. Ndc, in terms of size and business model, fully satisfies the pursuit of one of our goals: to reach US dentists everywhere. Ndc allows this, thanks to a dense network of local and/or regional distributors, widespread and punctually spread even in the smallest and most remote US provinces”.

comments